LLY stock trades at 40 times trailing earnings as demand for weight-loss drugs drives valuation higher.
Eli Lilly’s market capitalization has returned to $1 trillion, reflecting strong investor confidence in its GLP-1 weight-loss drugs, Mounjaro and Zepbound. The stock has risen 5% this year and over 400% in five years, though its valuation at 40 times trailing earnings raises concerns about sustainability.
The company’s growth is fueled by expanding sales of its GLP-1 therapies, which already generate billions annually but are expected to grow further. Recent acquisitions, including Orna Therapeutics and additions to its infectious disease portfolio, signal aggressive expansion into new therapeutic areas.
Despite high valuations, Eli Lilly’s long-term prospects remain robust, supported by its financial strength and pipeline development.